^
    Back
    Association details:
    Biomarker:MET amplification + RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib

    Published date:
    10/20/2020
    Excerpt:
    MET amplification was identified in post-treatment biopsies in four patients with RET fusion-positive NSCLC treated with selpercatinib….Using SPPs, selpercatinib with crizotinib were given together generating anecdotal evidence of clinical activity and tolerability, with one response lasting 10 months.
    DOI:
    10.1158/1078-0432.CCR-20-2278